Search

Displaying results 5551 - 5560 of 10000 in total
  1. Drug

    Parthenolide

    go.drugbank.com/drugs/DB13063
    ApprovedInvestigational

    Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.

  2. Drug

    Butaperazine

    go.drugbank.com/drugs/DB13213
    Approved

    Butaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397].

  3. Drug

    Florantyrone

    go.drugbank.com/drugs/DB08975
    ApprovedWithdrawn

    Florantyrone is used in the treatment of biliary dyskinesia

  4. Drug

    PV903

    go.drugbank.com/drugs/DB05163
    Experimental

    PV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage, resulting from an intolerant immune response to the developing foetus.

  5. Drug

    Vanillic acid

    go.drugbank.com/drugs/DB02130
    Experimental

    It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13).

  6. Drug

    2'-Deoxycytidine-5'-Monophosphate

    go.drugbank.com/drugs/DB03798
    Experimental

    A deoxycytosine nucleotide containing one phosphate group esterified to the deoxyribose moiety in the 2'-,3'- or 5- positions. [PubChem]

  7. Drug

    Anivamersen

    go.drugbank.com/drugs/DB16089
    Investigational

    Anivamersen is under investigation in clinical trial NCT01848106 (A Study to Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI).

  8. Drug

    Tegileridine

    go.drugbank.com/drugs/DB18988
    Investigational

    Tegileridine is under investigation in clinical trial NCT06458400 (To Evaluate the Efficacy and Safety of Tegileridine and Oliceridine Injections in the Treatment of Postoperative Pain).

  9. Drug

    Itolizumab

    go.drugbank.com/drugs/DB16207
    Investigational

    Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

  10. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels.